<DOC>
	<DOCNO>NCT01665625</DOCNO>
	<brief_summary>Systemic chemotherapy cytotoxic drug limit effectiveness advance pancreatic cancer patient . Gemcitabine use first-line drug advance pancreatic cancer two decade combination gemcitabine different chemotherapeutic drug investigate improve outcome pancreatic cancer . However , substantial improvement patient survival achieve . Locoregional chemotherapy via intra-arterial perfusion chemoemoblization take advantage increase local drug concentration reduce systemic toxicity . In study , investigator hypothesis artery infusion chemotherapy well antitumor effect systemic chemotherapy . The investigator analyze evaluate effect safety implant percutaneous left subclavian artery port-catheter drug delivery system regional chemotherapy inoperable pancreatic carcinoma .</brief_summary>
	<brief_title>Regional Versus Systemic Chemotherapy Treatment Unresectable Pancreatic Cancer</brief_title>
	<detailed_description />
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<criteria>Signed write informed consent Karnofsky score &gt; 60 , Expected survival &gt; 3 month , Liver , kidney function routine blood test within normal range No serious cardiopulmonary dysfunction No acute infection Pregnant lactate woman Uncontrolled internal disease Past presence malignancy Those receive immunosuppressive therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Pancreatic cancer</keyword>
	<keyword>Intra-arterial infusion</keyword>
	<keyword>Gemcitabine</keyword>
</DOC>